NTRK1 and neoplasm: Patients with microsatellite instability-high (MSI-H) or NTRK fusions have benefitted from immune checkpoint inhibitors or TRK inhibitors in tumor-agnostic basket trials, and subsets of patients received these treatments in the present study [41,42,43].